Story · Medicine & Biotech
Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
1 outlet · first reported by Medical Xpress on
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of… (Medical Xpress)
Coverage, in order
-
Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancerCombining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.